Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Stock Information for Aclarion Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aclarion Inc.

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
Aclarion to Present at the 20th Annual LD Micro Main Event
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Aclarion Announces Addition of University of Arizona College of Medicine - Phoenix as CLARITY Trial Site
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.